Ceremed’s first commercial product, Ostene^®, received FDA 510(k) approval for use as a biodissolvable bone hemostasis material in 2004. Utilizing proprietary technology Ostene^® has revolutionized the bone hemostasis market by solving well known surgical issues. The company’s focus involves partnerships with leading universities and medical device/pharmaceutical manufacturers to produce breakthrough products using proprietary polymer technologies. This strategy allows Ceremed to concentrate on product development, clinical trials, the development of strong intellectual property positions and regulatory approvals.

Ceremed is a leading innovator in the development of next generation medical products using proprietary polymer technology. These products include Ostene^®, Porous Polyethylene (PPE) Implants for reconstructive surgery, AOC PolymerBlend™ coatings and AOC PolymerBlend™ carrier systems for bioactive ingredients.

Ceremed maintains substantial IP positions within the biocompatible polymer and device space with numerous patents covering a wide variety of technologies and applications.

Regulatory Certifications
The company is certified to ISO 13485 by the British Standards Institute, which also serves as the notified body for the Ostene^® CE mark. The facility is registered with the FDA and holds a State of California medical device-manufacturing license.

Mission statement
Our mission is to provide the global medical community with superior biocompatible polymer solutions to improve clinical outcomes and patient quality of life.